JP7274469B2 - Ｃｄ３９／ｃｄ７３軸によるｔ細胞活性の回復 - Google Patents

Ｃｄ３９／ｃｄ７３軸によるｔ細胞活性の回復 Download PDF

Info

Publication number
JP7274469B2
JP7274469B2 JP2020519404A JP2020519404A JP7274469B2 JP 7274469 B2 JP7274469 B2 JP 7274469B2 JP 2020519404 A JP2020519404 A JP 2020519404A JP 2020519404 A JP2020519404 A JP 2020519404A JP 7274469 B2 JP7274469 B2 JP 7274469B2
Authority
JP
Japan
Prior art keywords
antibody
antibodies
cells
binding
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020519404A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020536109A5 (enExample
JP2020536109A (ja
Inventor
ステファニー・シャントゥー
ニコラ・グルダン
カリーヌ・パトゥレル
イヴァン・ペロ
バンジャマン・ロッシ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innate Pharma SA
Original Assignee
Innate Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma SA filed Critical Innate Pharma SA
Publication of JP2020536109A publication Critical patent/JP2020536109A/ja
Publication of JP2020536109A5 publication Critical patent/JP2020536109A5/ja
Application granted granted Critical
Publication of JP7274469B2 publication Critical patent/JP7274469B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
JP2020519404A 2017-10-06 2018-10-05 Ｃｄ３９／ｃｄ７３軸によるｔ細胞活性の回復 Active JP7274469B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762568812P 2017-10-06 2017-10-06
US62/568,812 2017-10-06
US201862686143P 2018-06-18 2018-06-18
US62/686,143 2018-06-18
PCT/EP2018/077217 WO2019068907A1 (en) 2017-10-06 2018-10-05 RESTORATION OF T CELL ACTIVITY BY AXIS CD39 / CD73

Publications (3)

Publication Number Publication Date
JP2020536109A JP2020536109A (ja) 2020-12-10
JP2020536109A5 JP2020536109A5 (enExample) 2021-10-21
JP7274469B2 true JP7274469B2 (ja) 2023-05-16

Family

ID=63799006

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020519404A Active JP7274469B2 (ja) 2017-10-06 2018-10-05 Ｃｄ３９／ｃｄ７３軸によるｔ細胞活性の回復

Country Status (11)

Country Link
US (2) US20190218308A1 (enExample)
EP (1) EP3692068B1 (enExample)
JP (1) JP7274469B2 (enExample)
KR (1) KR102710877B1 (enExample)
CN (1) CN111542539B (enExample)
AU (1) AU2018346447B2 (enExample)
BR (1) BR112020006809A2 (enExample)
CA (1) CA3074588A1 (enExample)
IL (1) IL273414A (enExample)
SG (1) SG11202002192QA (enExample)
WO (1) WO2019068907A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2238170T (pt) 2008-01-31 2017-02-21 Inserm - Inst Nat De La Santé Et De La Rech Médicale Anticorpos contra cd39 humano e seu uso para inibição da actividade de células t reguladoras
GB2545676A (en) * 2015-12-21 2017-06-28 Dublin Inst Of Tech Prediction of therapeutic response using vibrational spectroscopy
IL269150B2 (en) 2017-03-16 2025-04-01 Innate Pharma Cancer treatment preparations and methods
JP7113071B2 (ja) 2017-07-31 2022-08-04 トリシュラ セラピューティクス， インコーポレイテッド 抗ｃｄ３９抗体、抗ｃｄ３９抗体を含む組成物、および抗ｃｄ３９抗体を使用する方法
MX2020011588A (es) 2018-05-03 2020-12-07 Shanghai Epimab Biotherapeutics Co Ltd Anticuerpos de alta afinidad a pd-1 y lag-3 y proteinas de union bispecificas preparadas a partir de las mismas.
TWI870353B (zh) 2018-06-18 2025-01-21 法商天賜製藥公司 用於治療癌症之組合物及方法
CN113454121B (zh) * 2019-08-21 2022-03-08 和铂医药(上海)有限责任公司 抗cd73抗体及其应用
KR20220050971A (ko) * 2019-08-27 2022-04-25 엘피사이언스 (쑤저우) 바이오파마, 엘티디. 신규 항-cd39 항체
CN110407941B (zh) * 2019-09-25 2020-01-14 上海岸迈生物科技有限公司 Cd39的高亲和力抗体及其用途
TW202118791A (zh) 2019-11-05 2021-05-16 大陸商北京加科思新藥研發有限公司 對cd39具有特異性的結合分子及其用途
CA3165384A1 (en) * 2019-12-19 2021-06-24 Board Of Regents, The University Of Texas System Methods for treating glioblastoma
CN114106160A (zh) * 2020-08-28 2022-03-01 安源医药科技（上海）有限公司 抗SARS-CoV-2病毒单克隆抗体及应用
US20220133902A1 (en) * 2020-11-04 2022-05-05 Heidelberg Pharma Research Gmbh Composition Comprising a Combination of Immune Checkpoint Inhibitor and Antibody-Amatoxin Conjugate for Use in Cancer Therapy
JP2024507823A (ja) * 2021-02-19 2024-02-21 ヤンセン バイオテツク，インコーポレーテツド 免疫監視を増強するために制御性ｔ細胞を標的化するための材料及び方法
AU2022236461A1 (en) 2021-03-19 2023-10-05 Heidelberg Pharma Research Gmbh B-lymphocyte specific amatoxin antibody conjugates
CN119569881B (zh) 2022-03-03 2025-11-07 艾库斯生物科学有限公司 抗cd39抗体及其用途
US20250361314A1 (en) * 2022-06-08 2025-11-27 Shanghai Huaota Biopharmaceutical Co., Ltd. Cd39/cd73 bispecific antigen binding protein and use thereof
WO2024197020A2 (en) * 2023-03-21 2024-09-26 Beam Therapeutics Inc. Immunosuppressant-resistant modified allogeneic modified immune cells and methods for use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011510953A (ja) 2008-01-31 2011-04-07 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エト・ドゥ・ラ・ルシェルシュ・メディカル） 制御性ｔ細胞活性を抑制するための、ヒトｃｄ３９に対する抗体およびその使用
WO2016055609A1 (en) 2014-10-10 2016-04-14 Innate Pharma Cd73 blockade
WO2017089334A1 (en) 2015-11-23 2017-06-01 Innate Pharma Cd39 vascular isoform targeting agents

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5660827A (en) 1992-03-05 1997-08-26 Board Of Regents, The University Of Texas System Antibodies that bind to endoglin
US6387645B1 (en) * 1998-07-16 2002-05-14 Hyseq, Inc. Methods and materials relating to novel CD39-like polypeptides
EP2418278A3 (en) 2005-05-09 2012-07-04 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
KR101607288B1 (ko) 2005-07-01 2016-04-05 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
WO2009014708A2 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
CN104548091A (zh) 2008-02-11 2015-04-29 治疗科技公司 用于肿瘤治疗的单克隆抗体
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
TWI729512B (zh) 2008-12-09 2021-06-01 美商建南德克公司 抗pd-l1抗體及其於增進t細胞功能之用途
CN104961829B (zh) 2009-11-24 2018-08-21 米迪缪尼有限公司 针对b7-h1的靶向结合剂
DK2699264T3 (en) 2011-04-20 2018-06-25 Medimmune Llc ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1
BR122022000334B1 (pt) 2011-08-01 2023-03-21 Genentech, Inc Composição farmacêutica compreendendo um antagonista de ligação ao eixo pd-1 e um inibidor de mek
RU2656183C2 (ru) * 2012-02-07 2018-05-31 Иннейт Фарма Связывающие mica агенты
FR3011240A1 (fr) 2013-10-01 2015-04-03 Centre Nat Rech Scient Inhibiteurs de 5'-nucleotidases et leurs utilisations therapeutiques
PL3081576T3 (pl) 2013-12-12 2020-03-31 Shanghai Hengrui Pharmaceutical Co., Ltd. Przeciwciało anty pd-1, jego fragment wiążący antygen i ich zastosowanie medyczne
WO2015164573A1 (en) 2014-04-25 2015-10-29 Vitae Pharmaceuticals, Inc. Purine derivatives as cd73 inhibitors for the treatment of cancer
CN112778418B (zh) 2014-11-10 2025-04-22 免疫医疗有限公司 对cd73具有特异性的结合分子及其用途
HK1246304A1 (zh) * 2014-11-11 2018-09-07 Medimmune Limited 包含抗cd73抗体和a2a受体抑制剂的治疗组合及其用途
TWI711630B (zh) 2014-11-21 2020-12-01 美商必治妥美雅史谷比公司 抗ｃｄ７３抗體及其用途
EP3259288A1 (en) 2015-02-20 2017-12-27 Innate Pharma Cd73 blockade
WO2017064043A1 (en) * 2015-10-12 2017-04-20 Innate Pharma Cd73 blocking agents
WO2017098421A1 (en) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
WO2017100670A1 (en) 2015-12-09 2017-06-15 Corvus Pharmaceuticals, Inc. Humanized anti-cd73 antibodies
EA038565B1 (ru) 2016-01-08 2021-09-15 Аркус Байосайенсиз, Инк. Модуляторы экто-5'-нуклеотидазы и их применение
WO2017153952A1 (en) 2016-03-10 2017-09-14 Glaxosmithkline Intellectual Property Development Limited 5-sulfamoyl-2-hydroxybenzamide derivatives
TWI786072B (zh) 2016-11-18 2022-12-11 美商阿克思生物科學有限公司 Cd-73介導免疫抑制之抑制劑
IL269150B2 (en) * 2017-03-16 2025-04-01 Innate Pharma Cancer treatment preparations and methods
CN111372606B (zh) * 2017-11-15 2024-02-20 先天制药公司 增强atp释放作用
EP3959239A1 (en) * 2019-04-23 2022-03-02 Innate Pharma Cd73 blocking antibodies
AU2020328507A1 (en) * 2019-08-12 2022-03-17 Purinomia Biotech, Inc. Methods and compositions for promoting and potentiating T-cell mediated immune responses through ADCC targeting of CD39 expressing cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011510953A (ja) 2008-01-31 2011-04-07 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エト・ドゥ・ラ・ルシェルシュ・メディカル） 制御性ｔ細胞活性を抑制するための、ヒトｃｄ３９に対する抗体およびその使用
WO2016055609A1 (en) 2014-10-10 2016-04-14 Innate Pharma Cd73 blockade
WO2017089334A1 (en) 2015-11-23 2017-06-01 Innate Pharma Cd39 vascular isoform targeting agents

Also Published As

Publication number Publication date
BR112020006809A2 (pt) 2020-10-06
CA3074588A1 (en) 2019-04-11
KR20200060471A (ko) 2020-05-29
AU2018346447A1 (en) 2020-03-19
KR102710877B1 (ko) 2024-09-26
EP3692068A1 (en) 2020-08-12
CN111542539A (zh) 2020-08-14
SG11202002192QA (en) 2020-04-29
IL273414A (en) 2020-05-31
AU2018346447B2 (en) 2025-06-19
US20230099801A1 (en) 2023-03-30
JP2020536109A (ja) 2020-12-10
WO2019068907A1 (en) 2019-04-11
US20190218308A1 (en) 2019-07-18
CN111542539B (zh) 2023-10-20
EP3692068B1 (en) 2022-12-07

Similar Documents

Publication Publication Date Title
JP7274469B2 (ja) Ｃｄ３９／ｃｄ７３軸によるｔ細胞活性の回復
JP7132981B2 (ja) Ｃｄ７３遮断
KR102584011B1 (ko) 암 치료를 위한 조성물 및 방법
US11130817B2 (en) CD73 blocking agents
AU2018368541B2 (en) Potentiating the effect of ATP release
US20180030144A1 (en) Cd73 blockade
WO2016131950A1 (en) Cd73 blockade
EA044293B1 (ru) Восстановление активности t-клеток посредством системы cd39/cd73
EA045378B1 (ru) Усиление эффекта от высвобождения аденозинтрифосфата (атф)
BR112017006464B1 (pt) Anticorpo isolado, composição farmacêutica, uso de um anticorpo e anticorpo

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210908

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210908

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230123

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230425

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230501

R150 Certificate of patent or registration of utility model

Ref document number: 7274469

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150